Company Overview of New Haven Pharmaceuticals, Inc.
New Haven Pharmaceuticals, Inc. develops prescription pharmaceuticals that utilize currently marketed drugs or generally recognized as safe active pharmaceutical ingredients for therapeutic applications. It offers NHP-554C, an anti-platelet aspirin product for patients at higher risk for a secondary stroke/acute cardiac event that slowly releases into the bloodstream over 24 hours; NHP-554CZ, an anti-platelet aspirin product incorporating Yale University technology utilizing zinc salts; and NHP-229 for the purpose of lowering stomach acid alone or in combination with other drugs. The company was founded in 2008 and is based in New Haven, Connecticut.
142 Temple Street
New Haven, CT 06510
Founded in 2008
Key Executives for New Haven Pharmaceuticals, Inc.
Chief Executive Officer, President and Director
Co-Founder and Executive Chairman
Executive Vice President of Operations and Director
Vice President of Regulatory Affairs
Compensation as of Fiscal Year 2015.
New Haven Pharmaceuticals, Inc. Key Developments
New Haven Pharmaceuticals Receives FDA Approval for DURLAZA Extended Release Capsules for Secondary Prevention of Stroke and Acute Cardiac Events
Sep 8 15
New Haven Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved DURLAZA (aspirin), the first and only 24-hour, Extended Release Capsules, (162.5mg) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack). Low-dose aspirin has been proven to reduce the risk of secondary cardiovascular events and mortality in high-risk patients with stable cardiovascular disease. This is primarily due to aspirin's ability to inhibit platelet aggregation (blood clotting). While the body is making platelets 24-hours a day, current immediate-release traditional aspirin only stays in the blood for about a mean duration of four to six hours, with peak plasma concentrations peaking after just 30 minutes. DURLAZA utilizes extended-release, microcapsule technology to prolong aspirin release. DURLAZA offers the only once-daily, 24- hour antiplatelet therapy through the extended release of its 162.5mg dose, resulting in prolonged absorption, and sustained platelet exposure to aspirin. DURLAZA, like immediate-release aspirin, increases the risk of bleeding and gastric ulceration, and may cause fetal harm when administered to a pregnant woman.
New Haven Pharmaceuticals, Inc. Announces Executive Appointments
Oct 8 14
New Haven Pharmaceuticals, Inc. has strengthened its management team with the appointment of two experienced pharmaceutical executives to newly-created positions: Dr. Jeffrey Patrick as Chief Scientific Officer, and Michael Richardson as Chief Business Officer. Jeff Patrick, Pharm.D., joins NHP from Mallinckrodt Pharmaceuticals (formerly Covidien), where he most recently was Global Vice President of Medical Affairs. Mr. Richardson joins NHP from Grünenthal USA, where he served most recently as Head of Commercial Affairs.
New Haven Pharmaceuticals, Inc. Appoints Larry Dillaha as Executive Vice President Operations
Apr 2 14
New Haven Pharmaceuticals, Inc. announced the appointment of Larry Dillaha, M.D., to the newly-created position of Executive Vice President Operations. Dr. Dillaha joins the company from Insys Therapeutics, Inc. where he served as Chief Medical Officer since April 2010. Prior to joining New Haven Pharmaceuticals, Dr. Dillaha served as Chief Medical Officer of Insys Therapeutics.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 6, 2015